enoxacin Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antibacterials, nalidixic acid derivatives 1013 74011-58-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • enoxacin
  • enofloxacin
  • enofloxacine
  • enoksetin
  • enoxacine
A broad-spectrum 6-fluoronaphthyridinone antibacterial agent that is structurally related to NALIDIXIC ACID.
  • Molecular weight: 320.32
  • Formula: C15H17FN4O3
  • CLOGP: -1.60
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 2
  • TPSA: 85.77
  • ALOGS: -2.47
  • ROTB: 3

  • Status: OFM

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.80 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 4 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.60 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 45 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 62.44 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 87 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 2 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 5.40 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.80 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 5.10 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 31, 1991 FDA

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

Pharmacologic Action:

SourceCodeDescription
ATC J01MA04 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
QUINOLONE ANTIBACTERIALS
Fluoroquinolones
CHEBI has role CHEBI:36047 antibacterial drug
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000970 Antineoplastic Agents
MeSH PA D065609 Cytochrome P-450 CYP1A2 Inhibitors
MeSH PA D065607 Cytochrome P-450 Enzyme Inhibitors
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D065606 Metabolic Side Effects of Drugs and Substances
MeSH PA D059005 Topoisomerase II Inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Gonorrhea indication 15628003 DOID:7551
Acute gonococcal cervicitis indication 20943002 DOID:10615
Acute gonococcal urethritis indication 29864006
Gonorrhea of rectum indication 42746002
Urinary tract infectious disease indication 68566005
Gonorrhea of pharynx indication 74372003
Chancroid off-label use 266143009 DOID:13778

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 6.14 acidic
pKa2 8.63 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
V-type proton ATPase subunit B, brain isoform Enzyme IC50 5 CHEMBL
Topoisomerase IV Enzyme INHIBITOR CHEMBL CHEMBL
DNA gyrase Enzyme INHIBITOR CHEMBL CHEMBL
DNA gyrase subunit A Enzyme WOMBAT-PK

External reference:

IDSource
4020144 VUID
N0000148115 NUI
C0014310 UMLSCUI
D00310 KEGG_DRUG
325OGW249P UNII
5351 INN_ID
96084004 SNOMEDCT_US
3925 RXNORM
387550004 SNOMEDCT_US
4658 MMSL
d00099 MMSL
4020144 VANDF
003660 NDDF
CHEMBL826 ChEMBL_ID
DB00467 DRUGBANK_ID
CHEBI:157175 CHEBI
3229 PUBCHEM_CID
D015365 MESH_DESCRIPTOR_UI
8882 IUPHAR_LIGAND_ID

Pharmaceutical products:

None